This coincides with a recent study reporting germline POLE and POLQ variants in African American PCa patients44, while the reported benefit for Durvalumab therapy in colorectal cancer patients with germline POLE mutations45 holds potential for PCa precision oncology. The gene discussed is POLE; the disease is posterior cortical atrophy.